Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989196 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
A Phase 2 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00989196 is a Phase 2 study that has completed, run by Octapharma. The registered enrollment target is 22 participants.
The verdict
NCT00989196, a Phase 2 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII, a newly developed human cell-line derived recombinant FVIII concentrate in previously treated patients with severe Hemophilia A.
Interventions
- BIOLOGICAL Human-cl rhFVIII
- BIOLOGICAL Kogenate FS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00989196
The ClinicalTrials.gov registry entry for NCT00989196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Human-cl rhFVIII is the first listed.
NCT00989196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00989196 about?
NCT00989196 is a clinical study titled "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A". This is a clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII, a newly developed human cell-line derived recombinant FVIII concentrate in previously treated patients with severe Hemophilia A.
What is the current status of trial NCT00989196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2010-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00989196?
The interventions under investigation include: Human-cl rhFVIII (BIOLOGICAL), Kogenate FS (BIOLOGICAL).
Who is sponsoring clinical trial NCT00989196?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.